Coste-Burel M, Mainard F, Chivot L, Auget J L, Madec Y
Laboratoire de Biochimie A, Hotel Dieu, CHU, Nantes, France.
Clin Chem. 1990 Nov;36(11):1889-91.
Lipids, apolipoproteins, and LpAI and LpAI:AII particles were studied in 43 men (mean age 51, SD 7, years) 24 h before their coronary bypass surgery and in 54 control men (mean age 46 SD 9, years). LpAI and LpAI:AII were analyzed by electroimmunodiffusion and by a noncompetitive enzyme-linked immunoassay, respectively. Concentrations of LpAI and LpAI:AII in the bypass patients were significantly lower (P less than 0.001) than those in the controls. Apolipoprotein AI was significantly correlated with LpAI (P less than 0.001) and LpAI:AII (P less than 0.01) in controls, but only with LpAI:AII (P less than 0.001) in bypass patients. Discriminant analysis between controls and patients showed apolipoprotein AI to be the most powerful discriminant factor; the addition of LpAI and LpAI:AII did not improve discriminant power. We conclude that the determination of LpAI and LpAI:AII particles reflects metabolic disorders in patients but does not significantly influence the discrimination of such patients into risk groups.
在43名男性（平均年龄51岁，标准差7岁）进行冠状动脉搭桥手术前24小时以及54名对照男性（平均年龄46岁，标准差9岁）中研究了脂质、载脂蛋白以及LpAI和LpAI:AII颗粒。分别通过电免疫扩散法和非竞争性酶联免疫分析法对LpAI和LpAI:AII进行分析。搭桥手术患者中LpAI和LpAI:AII的浓度显著低于对照组（P<0.001）。在对照组中，载脂蛋白AI与LpAI（P<0.001）和LpAI:AII（P<0.01）显著相关，但在搭桥手术患者中仅与LpAI:AII（P<0.001）相关。对照组与患者之间的判别分析表明，载脂蛋白AI是最有力的判别因素；添加LpAI和LpAI:AII并未提高判别能力。我们得出结论，LpAI和LpAI:AII颗粒的测定反映了患者的代谢紊乱，但对将此类患者区分为风险组并无显著影响。
